Form 4: Altimmune Director Catherine A. Sohn Reports Stock Option Grant
SEC Form 4 Filing
Catherine A. Sohn, a director of Altimmune, Inc., reported the acquisition of stock options to purchase 18,600 shares of common stock.
Summary
- On February 6, 2025, Catherine A. Sohn, a director of Altimmune, Inc., reported the acquisition of stock options.
- The stock options grant allows Ms. Sohn to purchase 18,600 shares of Altimmune's common stock at an exercise price of $6.91 per share.
- The options vest in three tranches: 50% on July 15, 2025, 25% on September 30, 2025, and 25% on December 31, 2025, contingent upon continued service.
- Ms. Sohn also has a power of attorney designating Vipin K. Garg and Gregory Weaver to act on her behalf for SEC filings related to Altimmune securities.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing regarding stock option grants, which is generally neutral to positive as it incentivizes company leadership. The sentiment is moderately positive as it reflects standard corporate governance practices.
Positives
- The grant of stock options to a director aligns her interests with those of the shareholders.
- The vesting schedule incentivizes continued service and commitment to the company.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
- Companies like Moderna, BioNTech, and Novavax also utilize stock options as part of their compensation strategy to attract and retain talent.
- The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance and align with shareholder value.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/06/2025 | Date of the stock option transaction. |
| 02/07/2025 | Date of signature for the Form 4 filing. |
| 07/15/2025 | First vesting date for 50% of the stock options. |
| 09/30/2025 | Second vesting date for 25% of the stock options. |
| 12/31/2025 | Third vesting date for the remaining 25% of the stock options. |
| 02/06/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.